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Targeting human colorectal cancer cells using radiolabeled E. coli 
heat-stable enterotoxin analogs 
 
The guanylate cyclase C (GC-C) receptor protein is normally expressed at high levels on the luminal 
surface of the gastrointestinal epithelium.  Binding of the endogenous peptides guanylin and 
uroguanylin to GC-C initiates a signaling cascade, leading to phosphorylation of the cystic fibrosis 
transmembrane conductance regulator (CFTR).  Phosphorylation of CFTR opens the channel, resulting 
in net flow of water and Cl- ions into the intestinal lumen.  Perhaps via gene transfer from vertebrate 
hosts, enteropathogenic strains of E. coli have evolved a homologous peptide, the E. coli heat-stable 
enterotoxin (STh), which has the highest affinity for the GC-C receptor of any known ligand.  Expression 
of GC-C persists in mucosal cells that have undergone malignant transformation, providing a specific 
marker for human colorectal cancer.  Presentation of the GC-C receptor on the surface of colorectal 
cancer cells therefore provides a specific target for binding of radiolabeled heat-stable enterotoxin 
analogs.  The goal of the work presented here is to develop analogs of the STh with N-terminal pendant 
chelating moieties that can deliver imaging and therapeutic radionuclides to primary and metastatic 
colon cancer tissues.  Data will be presented relating to a modified STh analog.  This analog has been 
synthesized and labeled with nonradioactive indium and the radioisotope 111In.  The analog was 
evaluated for receptor binding affinity in vitro, as well as for in vivo pharmacokinetic characteristics in 
SCID mice with human colon cancer xenografts.  Receptor binding affinity was in the nanomolar range 
for both labeled and unlabeled peptides, and in vivo results demonstrated localization of radiolabel 
within the tumor mass.   
